SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nestor Marika 1976 ) "

Sökning: WFRF:(Nestor Marika 1976 )

  • Resultat 1-10 av 52
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Johansson, Patrik, et al. (författare)
  • A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma
  • 2020
  • Ingår i: Cell Reports. - : Elsevier BV. - 2211-1247. ; 32:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Glioblastoma (GBM) is a malignant brain tumor with few therapeutic options. The disease presents with a complex spectrum of genomic aberrations, but the pharmacological consequences of these aberrations are partly unknown. Here, we report an integrated pharmacogenomic analysis of 100 patient-derived GBM cell cultures from the human glioma cell culture (HGCC) cohort. Exploring 1,544 drugs, we find that GBM has two main pharmacological subgroups, marked by differential response to proteasome inhibitors and mutually exclusive aberrations in TP53 and CDKN2A/B. We confirm this trend in cell and in xenotransplantation models, and identify both Bcl-2 family inhibitors and p53 activators as potentiators of proteasome inhibitors in GBM cells, We can further predict the responses of individual cell cultures to several existing drug classes, presenting opportunities for drug repurposing and design of stratified trials. Our functionally profiled biobank provides a valuable resource for the discovery of new treatments for GBM.
  •  
2.
  • Lundsten, Sara, et al. (författare)
  • p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids
  • 2021
  • Ingår i: Biomolecules. - : MDPI. - 2218-273X. ; 11:11
  • Tidskriftsartikel (refereegranskat)abstract
    • p53 is involved in DNA damage response and is an exciting target for radiosensitization in cancer. Targeted radionuclide therapy against somatostatin receptors with 177Lu-DOTATATE is currently being explored as a treatment for neuroblastoma. The aim of this study was to investigate the novel p53-stabilizing peptide VIP116 in neuroblastoma, both as monotherapy and together with 177Lu-DOTATATE. Five neuroblastoma cell lines, including two patient-derived xenograft (PDX) lines, were characterized in monolayer cultures. Four out of five were positive for 177Lu-DOTATATE uptake. IC50 values after VIP116 treatments correlated with p53 status, ranging between 2.8–238.2 μM. IMR-32 and PDX lines LU-NB-1 and LU-NB-2 were then cultured as multicellular tumor spheroids and treated with 177Lu-DOTATATE and/or VIP116. Spheroid growth was inhibited in all spheroid models for all treatment modalities. The most pronounced effects were observed for combination treatments, mediating synergistic effects in the IMR-32 model. VIP116 and combination treatment increased p53 levels with subsequent induction of p21, Bax and cleaved caspase 3. Combination treatment resulted in a 14-fold and 1.6-fold induction of MDM2 in LU-NB-2 and IMR-32 spheroids, respectively. This, together with differential MYCN signaling, may explain the varying degree of synergy. In conclusion, VIP116 inhibited neuroblastoma cell growth, potentiated 177Lu-DOTATATE treatment and could, therefore, be a feasible treatment option for neuroblastoma.
  •  
3.
  • Al-Ramadan, Afkar, et al. (författare)
  • Analysis of radiation effects in two irradiated tumor spheroid models
  • 2018
  • Ingår i: Oncology Letters. - : Spandidos Publications. - 1792-1074 .- 1792-1082. ; 15:3, s. 3008-3016
  • Tidskriftsartikel (refereegranskat)abstract
    • Multicellular spheroids have proven suitable as three-dimensional in vivo-like models of non-vascularized micrometastases. Unlike monolayer-based models, spheroids mirror the cellular milieu and the pathophysiological gradients inside tumor nodules. However, there is limited knowledge of the radiation effects at the molecular level in spheroids of human origin. The present study is a presentation of selected cell biological processes that may easily be analyzed with methods available at routine pathology laboratories. Using gamma irradiated pancreatic neuroendocrine BON1 and colonic adenocarcinoma HCT116 spheroids as model systems, the present study assessed the radiobiological response in these models. Spheroid growth after irradiation was followed over time and molecular responses were subsequently assessed with immunohistochemistry (IHC) staining for descriptive analyses and semi-automatic grading of apoptosis, G(2)-phase and senescence in thin sections of the spheroids. Growth studies demonstrated the BON1 spheroids were slower growing and less sensitive to radiation compared with the HCT116 spheroids. IHC staining for G2-phase was primarily observed in the outer viable P-cell layers of the spheroids, with the 6 Gy irradiated HCT116 spheroids demonstrating a very clear increase in staining intensity compared with unirradiated spheroids. Apoptosis staining results indicated increased apoptosis with increasing radiation doses. No clear association between senescence and radiation exposure in the spheroids were observed. The present results demonstrate the feasibility of the use of multicellular spheroids of human origin in combination with IHC analyses to unravel radiobiological responses at a molecular level. The present findings inspire further investigations, including other relevant IHC-detectable molecular processes in time-and radiation dose-dependent settings.
  •  
4.
  • Andrade, Fernanda, et al. (författare)
  • Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo
  • 2021
  • Ingår i: Journal of Controlled Release. - : Elsevier. - 0168-3659 .- 1873-4995. ; 331, s. 198-212
  • Tidskriftsartikel (refereegranskat)abstract
    • Colorectal cancer (CRC) is a highly prevalent disease worldwide. Patient survival is hampered by tumor relapse and the appearance of drug-resistant metastases, which are sustained by the presence of cancer stem cells (CSC). Specific delivery of anti-CSC chemotherapeutic drugs to tumors by using targeted drug delivery systems that can also target CSC sub-population might substantially improve current clinical outcomes. CD44v6 is a robust biomarker for advanced CRC and CSC, due to its functional role in tumorigenesis and cancer initiation process. Here, we show that CD44v6-targeted polymeric micelles (PM) loaded with niclosamide (NC S), a drug against CSC, is a good therapeutic strategy against colorectal CSC and circulating tumor cells (CTC) in vivo. HCT116 cells were sorted according to their CD44v6 receptor expression into CD44v6+ (high) and CDv44v6- (low) subpopulations. Accordingly, CD44v6+ cells presented stemness properties, such as overexpression of defined stemness markers (ALDH1A1, CD44v3 and CXCR4) and high capacity to form colonspheres in low attachment conditions. NC S-loaded PM functionalized with an antibody fragment against CD44v6 (Fab-CD44v6) presented adequate size, charge, and encapsulation efficiency. In addition, Fab-CD44v6 significantly increased PM internalization in CD44v6+ cells. Further, encapsulation of NCS improved its effectiveness in vitro, particularly against colonspheres, and allowed to increase its intravenous dosage in vivo by increasing the amount of NCS able to be administered without causing toxicity. Remarkably, functionalized PM accumulate in tumors and significantly reduce CTC in vivo. In conclusion, CD44v6 targeted PM meet the essential conditions to become an efficient anti-CSC therapy.
  •  
5.
  • Berglund, Hanna, et al. (författare)
  • p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
  • 2023
  • Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer. - 1619-7070 .- 1619-7089.
  • Tidskriftsartikel (refereegranskat)abstract
    • PurposeMolecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [177Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53 is a key player in the proapoptotic signalling in response to radiation-induced DNA damage and is therefore a potential target for radiosensitisation.MethodsThis study investigated the use of the p53 stabilising peptide VIP116 and [177Lu]Lu-DOTATATE, either alone or in combination, for treatment of neuroblastoma tumour xenografts in mice. Initially, the uptake of [177Lu]Lu-DOTATATE in the tumours was confirmed, and the efficacy of VIP116 as a monotherapy was evaluated. Subsequently, mice with neuroblastoma tumour xenografts were treated with placebo, VIP116, [177Lu]Lu-DOTATATE or a combination of both agents.ResultsThe results demonstrated that monotherapy with either VIP116 or [177Lu]Lu-DOTATATE significantly prolonged median survival compared to the placebo group (90 and 96.5 days vs. 50.5 days, respectively). Notably, the combination treatment further improved median survival to over 120 days. Furthermore, the combination group exhibited the highest percentage of complete remission, corresponding to a twofold increase compared to the placebo group. Importantly, none of the treatments induced significant nephrotoxicity. Additionally, the therapies affected various molecular targets involved in critical processes such as apoptosis, hypoxia and angiogenesis.ConclusionIn conclusion, the combination of VIP116 and [177Lu]Lu-DOTATATE presents a promising novel treatment approach for neuroblastoma. These findings hold potential to advance research efforts towards a potential cure for this vulnerable patient population.
  •  
6.
  • Bondza, Sina, et al. (författare)
  • Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent
  • 2020
  • Ingår i: mAbs. - : TAYLOR & FRANCIS INC. - 1942-0862 .- 1942-0870. ; 12:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Based on their mechanism of action, two types of anti-CD20 antibodies are distinguished: Type I, which efficiently mediate complement-dependent cytotoxicity, and Type II, which instead are more efficient in inducing direct cell death. Several molecular characteristics of these antibodies have been suggested to underlie these different biological functions, one of these being the manner of binding to CD20 expressed on malignant B cells. However, the exact binding model on cells is unclear. In this study, the binding mechanism of the Type I therapeutic antibodies rituximab (RTX) and ofatumumab (OFA) and the Type II antibody obinutuzumab (OBI) were established by real-time interaction analysis on live cells. It was found that the degree of bivalent stabilization differed for the antibodies: OFA was stabilized the most, followed by RTX and then OBI, which had the least amount of bivalent stabilization. Bivalency inversely correlated with binding dynamics for the antibodies, with OBI displaying the most dynamic binding pattern, followed by RTX and OFA. For RTX and OBI, bivalency and binding dynamics were concentration dependent; at higher concentrations the interactions were more dynamic, whereas the percentage of antibodies that bound bivalent was less, resulting in concentration-dependent apparent affinities. This was barely noticeable for OFA, as almost all molecules bound bivalently at the tested concentrations. We conclude that the degree of bivalent binding positively correlates with the complement recruiting capacity of the investigated CD20 antibodies.
  •  
7.
  •  
8.
  • Bondza, Sina (författare)
  • Deciphering Binding Patterns of Therapeutic Antibodies with Immune Cells : From Method Development to Application
  • 2020
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Reversible binding, for example between signaling molecules and receptors on the cell surface, is one of the main means to communicate information in cellular systems. Knowledge about how molecules interact is crucial for both understanding biological function and for therapeutic intervention. The cellular environment often makes ligand-receptor interactions complex with the membrane providing structural support and containing other components that interfere with the interaction. One of the fastest growing drug classes for targeting cellular receptors are monoclonal antibodies (mAb), in particular within oncology. Therapeutic mAbs can have direct effects on target cells mediated via the Fab-domain and immune-related effects that are mediated via the Fc-domain. An example of the latter is activation of the complement system by binding of its first component C1q to Fc-domains. Furthermore, immune cells can recognize Fc-domains via Fc-receptors and cause target cell death by a process called antibody-dependent cellular cytotoxicity (ADCC).Increased understanding about structure-binding-function relationships facilitates rational drug design, as has been demonstrated with the development of next-generation mAbs that harbor a structural modification on their Fc-domain that strengthens the interaction with immune cells thereby increasing ADCC efficacy. In this thesis, assays for characterizing mAb binding and mAb mediated interactions on live cells were developed and applied to illustrate how detailed knowledge about binding processes helps to understand the relation between binding and biological function.Paper I describes a protocol for real-time interaction analysis of antibodies with live immune cells enabling binding measurements in a relevant cellular context with the data resolution needed to study complex binding processes.Paper II presents a novel real-time proximity assay that allows to study binding kinetics in connection with receptor dimerization and clustering thereby aiding in decipher complex interactions.In paper III, binding patterns of the CD20 mAbs rituximab, ofatumumab and obinituzumab were established on cells revealing that the fraction of bivalently bound mAbs differed resulting in dose-dependent affinities for rituximab and obinituzumab.In paper IV, a C1q binding assay to mAb opsonized cells was developed and it was shown that a higher degree of bivalent binding correlated with stronger C1q binding for the CD20 mAbs evaluated in paper III.In paper V, an assay to study mAb mediated cell-cell interactions was set-up and it was found that neutrophil engagement with target cells was similar for antibodies of IgG and IgA isotype.
  •  
9.
  • Bondza, Sina, et al. (författare)
  • Novel Real-Time Proximity Assay for Characterizing Multiple Receptor Interactions on Living Cells
  • 2017
  • Ingår i: Analytical Chemistry. - : American Chemical Society (ACS). - 0003-2700 .- 1520-6882. ; 89:24, s. 13212-13218
  • Tidskriftsartikel (refereegranskat)abstract
    • Cellular receptor activity is often controlled through complex mechanisms involving interactions with multiple molecules, which can be soluble ligands and/or other cell surface molecules. In this study, we combine a fluorescence-based technology for real-time interaction analysis with fluorescence quenching to create a novel time-resolved proximity assay to study protein-receptor interactions on living cells. This assay extracts the binding kinetics and affinity for two proteins if they bind in proximity on the cell surface. One application of real-time proximity interaction analysis is to study relative levels of receptor dimerization. The method was primarily evaluated using the HER2 binding antibodies Trastuzumab and Pertuzumab and two EGFR binding antibodies including Cetuximab. Using Cetuximab and Trastuzumab, proximity of EGFR and HER2 was investigated before and after treatment of cells with the tyrosine-kinase inhibitor Gefitinib. Treated cells displayed 50% increased proximity signal, whereas the binding characteristics of the two antibodies were not significantly affected, implying an increase in the EGFR-HER2 dimer level. These results demonstrate that real-time proximity interaction analysis enables determination of the interaction rate constants and affinity of two ligands while simultaneously quantifying their relative colocalization on living cells.
  •  
10.
  • Chandramohan, Arun, et al. (författare)
  • Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists
  • 2024
  • Ingår i: Nature Communications. - : Springer Nature. - 2041-1723. ; 15:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Although stapled α-helical peptides can address challenging targets, their advancement is impeded by poor understandings for making them cell permeable while avoiding off-target toxicities. By synthesizing >350 molecules, we present workflows for identifying stapled peptides against Mdm2(X) with in vivo activity and no off-target effects. Key insights include a clear correlation between lipophilicity and permeability, removal of positive charge to avoid off-target toxicities, judicious anionic residue placement to enhance solubility/behavior, optimization of C-terminal length/helicity to enhance potency, and optimization of staple type/number to avoid polypharmacology. Workflow application gives peptides with >292x improved cell proliferation potencies and no off-target cell proliferation effects ( > 3800x on-target index). Application of these ‘design rules’ to a distinct Mdm2(X) peptide series improves ( > 150x) cellular potencies and removes off-target toxicities. The outlined workflow should facilitate therapeutic impacts, especially for those targets such as Mdm2(X) that have hydrophobic interfaces and are targetable with a helical motif.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 52
Typ av publikation
tidskriftsartikel (44)
doktorsavhandling (4)
annan publikation (3)
konferensbidrag (1)
Typ av innehåll
refereegranskat (39)
övrigt vetenskapligt/konstnärligt (13)
Författare/redaktör
Nestor, Marika, 1976 ... (50)
Spiegelberg, Diana, ... (19)
Lundsten, Sara (14)
Lane, David P. (10)
Mortensen, Anja (9)
Stenerlöw, Bo (5)
visa fler...
Mohajershojai, Tabas ... (5)
Brown, Christopher J ... (5)
Haylock, Anna-Karin (5)
Mortensen, Anja C. (5)
Jha, Preeti (4)
Pettersson, Curt (4)
Sarmento, Bruno (4)
Spiegelberg, Diana (4)
Edwards, Katarina (3)
Brown, C (3)
Haglöf, Jakob (3)
Arvidsson, Torbjörn (3)
Hedeland, Mikael (3)
Frejd, Fredrik Y. (3)
Buijs, Jos (3)
Berglund, Hanna (3)
Bondza, Sina (3)
Erngren, Ida (3)
Lane, David Philip (3)
Lundqvist, Hans (2)
Ferreira, Daniel (2)
Krona, Cecilia, 1976 (2)
Abramenkovs, Andris (2)
Persson, Helena (2)
Nelander, Sven (2)
Nilvebrant, Johan (2)
Morin, Eric (2)
Sandström, Karl (2)
Wermeling, Fredrik (2)
Björkelund, Hanna, 1 ... (2)
ten Broeke, Toine (2)
Chandramohan, Arun (2)
Partridge, Anthony W ... (2)
Engskog, Mikael K R (2)
Oliveira, Carla (2)
Hofström, Camilla (2)
Spangler, Douglas (2)
Ingelshed, Katrine (2)
Kannan, Pavitra (2)
Jiang, Long (2)
Kennedy, Patrick J. (2)
Granja, Pedro L. (2)
Raval, Nakul (2)
Sarén, Tina (2)
visa färre...
Lärosäte
Uppsala universitet (52)
Karolinska Institutet (14)
Kungliga Tekniska Högskolan (4)
Göteborgs universitet (1)
Stockholms universitet (1)
Lunds universitet (1)
Språk
Engelska (52)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (46)
Naturvetenskap (11)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy